Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- 1st PAFSC Committee Recommends Approval for Products Including Eisai’s Lunesta
November 8, 2011
- MHLW Announces Additional Indications for 3 APIs Following Prior Assessments
November 7, 2011
- CSIMC Approves Plan to Ban Use of “Dispensing Point” Cards by Pharmacies, Drugstores
November 4, 2011
- CSIMC Subcommittee Approves Proposal to Expand Range of Drugs Subject to Re-pricing
November 4, 2011
- Japan, China, S. Korea Agree to Draft GL on Joint Clinical Trials
November 2, 2011
- Chuikyo Subcommittee Approves Proposal to Expand Range of Drugs Subject to Re-pricing
November 2, 2011
- Chuikyo Approves Plan to Ban Use of “Dispensing Point” Cards by Pharmacies, Drugstores
November 2, 2011
- Committee Recommends Approval of 3 Products Including MSD’s Rota Teq
November 1, 2011
- Business Sector Call for Japan to Join TPP Talks Voiced at National Strategy Council Meeting
November 1, 2011
- Korosho to Ask Doctors to Exercise Caution in Co-prescribing 3 or More Psychotropics
November 1, 2011
- Healthcare Reps at Chuikyo Call For Quality Assurance to Promote GE Use
November 1, 2011
- WT of DPJ Begins Discussion, Not Yet Known If It Covers Drug Pricing System
October 31, 2011
- Medical Benefits Rose 4.2% in FY2009, Breaking ¥30 Tril. for 1st Time
October 31, 2011
- Drug-induced Hepatitis Victims, Lawyers Petition Against Establishment of “Third Party Organization”
October 31, 2011
- MHLW Research Team Looks Into Compliance Systems, Gathering Advanced Case Studies
October 28, 2011
- CSIMC's Drug Price Committee Agrees to Review Foreign Price-Based Adjustments, Increase Downward Revising
October 28, 2011
- MHLW Varies Direction of Revision with Innovative Evaluation and Efficiency
October 28, 2011
- MHLW Calls for Package Insert Revisions for 6 Products Including Strattera
October 28, 2011
- US FDA Extends Action Date for SGLT-2 Inhibitor Dapagliflozin
October 28, 2011
- Mr Yoshimura of Astem to Be Named as Successor of Mr Matsutani: CSIMC Expert Member
October 28, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…